Sugi Predict

Sugi Predict / Compounds / SCHEMBL11733722

SCHEMBL11733722

SCHEMBL11733722

N[C@H](C(=O)O)c1ccc(Cl)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2C9 P11712 7/20 0.55
▸ MEN1 O00255 5/20 0.55
▸ KMT2A Q03164 5/20 0.55
▸ CYP2C19 P33261 5/20 0.55
▸ CYP2D6 P10635 3/20 0.55
▸ HSD17B10 Q99714 6/20 0.52
▸ TDP1 Q9NUW8 4/20 0.52
▸ DRD3 P35462 2/20 0.52
▸ GRM8 O00222 1/20 0.52
▸ GRM6 O15303 1/20 0.52
▸ SLC6A2 P23975 1/20 0.52
▸ SLC6A4 P31645 1/20 0.52
▸ GRM4 Q14833 1/20 0.52
▸ KDM4E B2RXH2 4/20 0.48
▸ ALDH1A1 P00352 4/20 0.48
▸ HPGD P15428 4/20 0.48
▸ GABBR2 O75899 3/20 0.48
▸ GABBR1 Q9UBS5 3/20 0.48
▸ GRM1 Q13255 3/20 0.48
▸ LMNA P02545 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL390594 1.00 CYP2C9 (0.55) CYP2C9MEN1KMT2ACYP2C19CYP2D6
SCHEMBL2896976 1.00 CYP2C9 (0.55) CYP2C9MEN1KMT2ACYP2C19CYP2D6
Hydrochloric Acid SCHEMBL28011489 0.98 CYP2C9 (0.53) CYP2C9MEN1KMT2ACYP2C19CYP2D6
Hydrochloric Acid SCHEMBL28524755 0.98 CYP2C9 (0.53) CYP2C9MEN1KMT2ACYP2C19CYP2D6
Hydrochloric Acid SCHEMBL29398375 0.98 CYP2C9 (0.53) CYP2C9MEN1KMT2ACYP2C19CYP2D6
SCHEMBL30057656 0.94 CYP2C9 (0.50) CYP2C9MEN1KMT2ACYP2C19CYP2D6
SCHEMBL13527786 0.88 HSD17B10 (0.61) CYP2C9MEN1KMT2ACYP2C19CYP2D6
SCHEMBL11520882 0.82 HSD17B10 (0.52) CYP2C9MEN1KMT2ACYP2C19CYP2D6
SCHEMBL14152516 0.82 ADRB2 (0.48) CYP2C9MEN1KMT2ACYP2C19CYP2D6
SCHEMBL28240348 0.82 BRD4 (0.61) CYP2C9MEN1KMT2ACYP2C19CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111153868-A Synthesis method of 4- (4-chlorphenyl) -2-trifluoromethyl-3-oxazole-5-ketone 山东省联合农药工业有限公司 2020-05-15 — — CN claimed
US-4043991-A Preparation of peptides and cephalosporins SUMITOMO CHEMICAL COMPANY, LIMITED (JA) 1977-08-23 — — US claimed
US-20260083852-A1 PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR UNIV CALIFORNIA (US) 2026-03-26 — — US disclosed
US-12485182-B2 Proteoglycan mimetics for enhanced wound healing, angiogenesis, and vascular repair THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-12-02 — — US disclosed
US-12157778-B2 Peptides for activation of cell signaling in osteoprogenitor cells THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-12-03 — — US disclosed
EP-4425181-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTE Bertis Inc (KR) 2024-09-04 — — EP disclosed
US-20240011979-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTES BERTIS INC. (KR) 2024-01-11 — — US disclosed
US-20230346960-A1 PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-11-02 — — US disclosed
US-20230330065-A1 RelA Inhibitors for Biofilm Disruption DREXEL UNIVERSITY (US) 2023-10-19 — — US disclosed
US-20230330065-A1 RelA Inhibitors for Biofilm Disruption DREXEL UNIVERSITY (US) 2023-10-19 — — US disclosed
US-20230330065-A1 RelA Inhibitors for Biofilm Disruption DREXEL UNIVERSITY (US) 2023-10-19 — — US disclosed
US-4043991-A Preparation of peptides and cephalosporins SUMITOMO CHEMICAL COMPANY, LIMITED (JA) 1977-08-23 — — US disclosed
US-4009272-A ANTIBIOTIC BAYER AKTIENGESELLSCHAFT (DT) 1977-02-22 — — US disclosed
US-3983105-A Penicillins BAYER AKTIENGESELLSCHAFT (DT) 1976-09-28 — — US disclosed
US-3978056-A BACTERICIDES BAYER AKTIENGESELLSCHAFT (DT) 1976-08-31 — — US disclosed
US-3975375-A BACTERICIDES BAYER AKTIENGESELLSCHAFT (DT) 1976-08-17 — — US disclosed
US-3974142-A BACTERICIDES BAYER AKTIENGESELLSCHAFT (DT) 1976-08-10 — — US disclosed
US-3974141-A IMIDAZOLIDINYL-CARBAMIDOBACTERICIDES BAYER AKTIENGESELLSCHAFT (DT) 1976-08-10 — — US disclosed
US-3972869-A Penicillins BAYER AKTIENGESELLSCHAFT (DT) 1976-08-03 — — US disclosed
US-3972870-A IMIDAZOLIDINYL-CARBAMIDO-BACTERICIDES BAYER AKTIENGESELLSCHAFT (DT) 1976-08-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230346960-A1 PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR PDGFA, PDGFRB, TEK CYP2C9 4598/4885MEN1 4811/4885KMT2A 4334/4885
US-12485182-B2 Proteoglycan mimetics for enhanced wound healing, angiogenesis, and vascular repair PDGFA, PDGFRB, TEK CYP2C9 4598/4885MEN1 4811/4885KMT2A 4334/4885
US-20260083852-A1 PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR PDGFA, DCLRE1A, PDGFRA CYP2C9 4593/4885MEN1 4697/4885KMT2A 2690/4885
US-20230330065-A1 RelA Inhibitors for Biofilm Disruption RELA, NFKBIA, NFKB1 CYP2C9 3200/4885MEN1 4462/4885KMT2A 1797/4885
US-12157778-B2 Peptides for activation of cell signaling in osteoprogenitor cells ITGB4, ITGA4, ITGB1 CYP2C9 4633/4885MEN1 1806/4885KMT2A 3524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.